Merck Millipore announces incoming CEO and president
Merck Millipore, the life science division of Merck, has announced the appointment of Dr Udit Batra as its incoming president and CEO.
Dr Batra comes to Merck Millipore from the consumer health division of Merck KGaA, where he successfully grew the business in established and emerging markets. He previously worked at Novartis Vaccines and Diagnostics, where he was Head of Global Public Health and Market Access. Prior to that, he served in a range of executive management positions at Novartis. He began his career as a research engineer at Merck & Co.
“As a former researcher who personally utilised the strong differentiated products that Merck Millipore offers, I have watched this organisation develop over the past several years, and look forward to further building upon that success to bring continued value to our customers and other stakeholders,” Dr Batra said.
Dr Batra holds a PhD in chemical engineering from Princeton University and a bachelor’s degree in chemical engineering from the University of Delaware. He will assume leadership at Merck Millipore effective 15 May and be based at the company’s US headquarters in Massachusetts.
Billion-dollar deal for UQ's molecular clamp vaccine tech
Sanofi has entered into an agreement to acquire Vicebio, a biotech company formed in 2018 to...
Director of scandal-ridden Forensic Science Queensland resigns
Dr Linzi Wilson-Wilde resigned from her position one month after being suspended by Queensland...
$492m pathology hub coming to Westmead Health Precinct
The NSW Health Pathology Statewide Hub will be delivered to Westmead Health Precinct, as part of...